Ralph Millett
Hematology & Oncology · New Orleans, LANPI 1932563152
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,488 of the $15,752 with a category attached, or 85.6%. 16 manufacturers reported payments, led by Genentech USA, Inc. at 56.1% of the total. 2025 is the largest year on record at $15,105, more than ten times the $31 reported in 2023.
Across 39 payments — averaging $403.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$9K
- Daiichi Sankyo Inc.$2K
- AstraZeneca$2K
- Amgen$2K
- Genentech, Inc.$306
- Johnson & Johnson$250
- plus $537 from 10 others
Across 1 payment — averaging $977.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$978
What the payments were for
- Consulting fees$13,48886%
- Travel & lodging$5704%
- Food & beverage$1,59510%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 5 | $8,833 |
| Daiichi Sankyo Inc. | 12 | $2,234 |
| AstraZeneca | 2 | $1,970 |
| Amgen | 1 | $1,623 |
| Genentech, Inc. | 2 | $306 |
| Johnson & Johnson | 2 | $250 |
| Pfizer | 2 | $154 |
| Tempus AI, Inc | 2 | $148 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| Merck | 2 | $46 |
| Beigene USA, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 1 | $26 |
| Array Biopharma Inc | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Novocure Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,752 in reported general payments places this provider in the 75th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 16 | $279,539 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $721 |
| Dexamethasone | 87 | $644 |
| Doxycycline Hyclate | 12 | $512 |
| Prochlorperazine Maleate | 47 | $438 |
| Olanzapine | 70 | $307 |
| Levothyroxine Sodium | 22 | $204 |
| Ondansetron OdtOndansetron | 11 | $177 |
| Potassium Chloride | 15 | $163 |
| Oxycodone Hcl | 17 | $142 |
| Duloxetine Hcl | 13 | $134 |
| Hydrocortisone | 11 | $122 |
| Prednisone | 32 | $92 |
| Pantoprazole Sodium | 11 | $77 |
| Folic Acid | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $1,970 | $279,53916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.